Compare Amgen, Inc. (AMGN) vs Uranium Energy Corp (UEC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Uranium Energy Corp — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Uranium Energy Corp trades at $10.41 (market cap $5.21B). The key difference: Amgen, Inc. is far larger — about 37.6× Uranium Energy Corp's market cap, and Amgen, Inc. pays a 2.77% dividend while Uranium Energy Corp pays none. Which is the better fit depends on your goals.
| AMGN | UEC | |
|---|---|---|
Market Cap | $196.12B | $5.21B |
Sector | Health | Energy |
52-Week High | $388.16 | $20.14 |
52-Week Low | $271.18 | $6.59 |
Enterprise Value | $241.41B | $4.72B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
UEC trades at $10.53, up 3.64% today, but technical indicators show a bearish trend with strong selling pressure. The company reported widening losses with negative net income margins and zero revenue in recent quarters, though it maintains $794 million in liquid assets and no debt. Analyst consensus remains overwhelmingly bullish with 87.5% buy ratings, citing strategic positioning in uranium production.
Investment outlook hinges on execution of production ramp-ups and uranium price recovery. Key opportunities include strategic assets and strong liquidity, while risks involve persistent losses, regulatory delays, and volatile commodity prices. The stock faces near-term pressure from weak fundamentals despite long-term nuclear energy tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
